PR Newswire02.13.17
Zimmer Biomet Holdings Inc. announced the international release of the Subchondroplasty (SCP) Procedure. The Company received CE mark approval for the commercialization of its SCP Procedure to facilitate distribution in the European Union (EU) and other countries that recognize the CE mark. Zimmer Biomet also received approval for distribution in Canada, Singapore, Malaysia and Hong Kong.
The SCP Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions (BMLs). Diagnosed using an MRI and physical exam, BMLs are associated with stress fractures or micro-fractures of the bone adjacent to the joint. Left untreated, these defects may lead to cartilage degeneration, limited function, pain and a greater risk for joint deterioration.
SCP is performed to repair chronic BMLs by filling them with AccuFill Bone Substitute Material, a porous injectable calcium phosphate (CaP). The bone substitute is then slowly resorbed and replaced with healthy bone, repairing the bone defect.
The procedure is usually performed along with arthroscopy for visualization and treatment of findings inside the joint. In some cases, an open or mini-open procedure is necessary for access to the defect.
"The Subchondroplasty procedure addresses a previously unmet need in my practice for patients with chronic and painful bone marrow lesions," said Dr. Christopher Baker, orthopedic surgeon at Florida Orthopedic Institute in Tampa, Fla. "These patients no longer benefit from conservative treatment, yet are not ready for total joint replacement surgery."
Initially used only in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including bones of the foot, ankle and hip. Zimmer Biomet now owns 36 patents and eight trademarks in this area, with numerous others still pending.
"The international release of the Subchondroplasty Procedure is a major milestone for our company and for patients with chronic bone marrow lesions," said David Nolan, Zimmer Biomet Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions. "The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch."
The SCP Procedure is a minimally invasive outpatient intervention that addresses the defects associated with subchondral bone marrow lesions (BMLs). Diagnosed using an MRI and physical exam, BMLs are associated with stress fractures or micro-fractures of the bone adjacent to the joint. Left untreated, these defects may lead to cartilage degeneration, limited function, pain and a greater risk for joint deterioration.
SCP is performed to repair chronic BMLs by filling them with AccuFill Bone Substitute Material, a porous injectable calcium phosphate (CaP). The bone substitute is then slowly resorbed and replaced with healthy bone, repairing the bone defect.
The procedure is usually performed along with arthroscopy for visualization and treatment of findings inside the joint. In some cases, an open or mini-open procedure is necessary for access to the defect.
"The Subchondroplasty procedure addresses a previously unmet need in my practice for patients with chronic and painful bone marrow lesions," said Dr. Christopher Baker, orthopedic surgeon at Florida Orthopedic Institute in Tampa, Fla. "These patients no longer benefit from conservative treatment, yet are not ready for total joint replacement surgery."
Initially used only in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including bones of the foot, ankle and hip. Zimmer Biomet now owns 36 patents and eight trademarks in this area, with numerous others still pending.
"The international release of the Subchondroplasty Procedure is a major milestone for our company and for patients with chronic bone marrow lesions," said David Nolan, Zimmer Biomet Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions. "The procedure offers a tool that fills a gap in the patient treatment algorithm for the surgeon. We are eager to begin our international commercial launch."